CIK 0001472091 · Non-accelerated filer<br>Smaller reporting company
PDS Biotechnology Corp
Sign in to watch- Ticker
- PDSB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 264231384
- Phone
- 800-208-3343
- Business address
- 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540
- Former names
- Edge Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-28 | Freitag Gregory Gene Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2022-06-02 | Brown Spencer D. Senior VP, General Counsel | Grant or award · Employee Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2022-01-19 | CONN GREGORY Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) | +112,100 | 112,100 | ||
| 2022-01-19 | BEDU-ADDO FRANK President/CEO | Grant or award · Stock Option (Right to Buy) | −291,500 | 291,500 | ||
| 2022-01-19 | WOOD LAUREN Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +88,600 | 88,600 | ||
| 2021-12-13 | HILL MATTHEW C Chief Financial Officer | Purchase | +2,500 | $9.00 | $23K | 3,475 |
| 2021-12-13 | HILL MATTHEW C Chief Financial Officer | Purchase | +400 | $8.90 | $4K | 3,875 |
| 2021-12-13 | HILL MATTHEW C Chief Financial Officer | Purchase | +100 | $9.00 | $900 | 3,975 |
| 2021-12-13 | HILL MATTHEW C Chief Financial Officer | Purchase | +100 | $9.00 | $900 | 4,075 |
| 2021-10-19 | HILL MATTHEW C Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +202,800 | 202,800 | ||
| 2021-06-17 | BRAWLEY OTIS W Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2021-06-17 | Glover Steve C Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2021-06-17 | Ali-Jackson Kamil Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2021-06-17 | SYKES RICHARD Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2021-06-17 | Iliev Ilian Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2021-06-17 | Freitag Gregory Gene Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2021-06-16 | Bloomquist DeLyle W See Remarks | Option exercise | +2,970 | $5.99 | $18K | 183,888 |
| 2021-06-16 | Bloomquist DeLyle W See Remarks | Purchase | +10,000 | $9.88 | $99K | 193,888 |
| 2021-06-16 | Bloomquist DeLyle W See Remarks | Option exercise · Stock Option (Right to Buy) | −2,970 | 6,030 | ||
| 2021-06-15 | BEDU-ADDO FRANK President/CEO | Option exercise | +53,174 | $6.57 | $349K | 673,681 |
Page 4 of 6 · 118 trades